Intravenous injection of siRNAs against ARHGEF4, CCDC88A, LAMTOR2, mTOR, NUP85, and WASF2, which were modified with FA to allow binding to the FA receptor and PEG-COL nanoparticles, enabled target siRNA-FA-PEG-COL nanoparticle-mediated passive delivery to human PDAC tumor cells and promoted efficient siRNA endocytosis of these siRNA particles via the FA receptor on PDAC cells. This evidence concerns the gene WASF2 and neoplasm.